The Board of Queensland Bauxite (ASX:QBL) is delighted to announce that Mineral Development License approval has been progressed for the South Johnstone Bauxite Project at Camp Creek in Queensland with the important decision received today from the DEHP to approve the amendment to our previous Environmental Authority, to allow for the work programme intended under the MDL.
Boehringer Ingelheim and pharmaceutical research company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim is initiating the Phase IIa study ROBIN. This marks the beginning of the clinical development program for BI 1467335 in a second indication targeting a severe diabetes complication. An already ongoing Phase II clinical study program is investigating the compound in NASH.
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.
Australian medical device company, Oventus Medical Ltd. (ASX:OVN) is pleased to release its Appendix 4E with its full year audited general purpose financial report for the period ending 30 June 2017.
The Directors of Chapmans Limited (ASX:CHP) are pleased to announce that the Company has entered into a Binding Heads of Agreement with MJ Life Sciences Pty Ltd, to make a strategic investment of US$500,000 in MJLS.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.6m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2017.
The Directors of Rhinomed Limited ASX:RNO) provide the following Report in relation to the Group for the year ended 30 June 2017.
